Beta Bionics, Inc. (NASDAQ:BBNX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Beta Bionics, Inc. (NASDAQ:BBNX) have been given a consensus rating of “Moderate Buy” by the eleven ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $23.20.

Several analysts have recently weighed in on the company. Lake Street Capital set a $20.00 target price on Beta Bionics in a research note on Wednesday, February 18th. UBS Group upgraded Beta Bionics to a “strong-buy” rating in a report on Monday, February 9th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $25.00 target price on shares of Beta Bionics in a research report on Thursday, January 15th. Bank of America downgraded shares of Beta Bionics from a “buy” rating to a “neutral” rating in a research report on Friday, January 9th. Finally, Robert W. Baird dropped their price target on shares of Beta Bionics from $28.00 to $14.00 and set a “neutral” rating for the company in a research note on Wednesday, February 18th.

Insider Activity at Beta Bionics

In other news, CFO Stephen Feider sold 20,000 shares of the firm’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $29.53, for a total value of $590,600.00. Following the transaction, the chief financial officer directly owned 42,614 shares in the company, valued at approximately $1,258,391.42. This trade represents a 31.94% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Mike Mensinger sold 2,200 shares of the stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $30.10, for a total transaction of $66,220.00. Following the sale, the insider owned 80,752 shares in the company, valued at approximately $2,430,635.20. This trade represents a 2.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 34,705 shares of company stock worth $945,653.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of BBNX. Eventide Asset Management LLC increased its stake in Beta Bionics by 0.8% during the 4th quarter. Eventide Asset Management LLC now owns 4,994,728 shares of the company’s stock valued at $152,233,000 after buying an additional 37,476 shares during the period. Farallon Capital Management LLC boosted its holdings in shares of Beta Bionics by 2.6% in the third quarter. Farallon Capital Management LLC now owns 4,313,920 shares of the company’s stock valued at $85,718,000 after acquiring an additional 110,000 shares in the last quarter. Soleus Capital Management L.P. increased its stake in shares of Beta Bionics by 12.5% during the second quarter. Soleus Capital Management L.P. now owns 3,820,158 shares of the company’s stock valued at $55,622,000 after acquiring an additional 424,817 shares during the period. Sands Capital Alternatives LLC raised its holdings in Beta Bionics by 15.0% during the second quarter. Sands Capital Alternatives LLC now owns 3,570,113 shares of the company’s stock worth $51,981,000 after purchasing an additional 466,331 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in Beta Bionics by 213.5% during the third quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company’s stock worth $44,036,000 after purchasing an additional 1,509,217 shares in the last quarter.

Beta Bionics Stock Performance

Shares of NASDAQ:BBNX opened at $11.11 on Friday. The stock has a 50-day simple moving average of $17.95 and a 200-day simple moving average of $22.27. The stock has a market capitalization of $493.08 million, a P/E ratio of -5.70 and a beta of 5.60. Beta Bionics has a 1 year low of $8.89 and a 1 year high of $32.71.

Beta Bionics (NASDAQ:BBNX) last announced its quarterly earnings results on Tuesday, February 17th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.12. Beta Bionics had a negative net margin of 73.02% and a negative return on equity of 20.29%. The firm had revenue of $32.12 million during the quarter.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.